Leucine

• 17/10/2023
• Series A
• $7,000,000

Leucine is an AI-powered platform that helps pharmaceutical manufacturers in staying compliant and audit-ready while ensuring their medicines reach the patients faster.

Using Leucine, the Manufacturing, QA, and QC teams can significantly increase productivity and reduce deviations from cGMP guidelines across thousands of complex regulated workflows from material receipt to batch release. Leucine supports manufacturers across all modalities such as small molecules, biologics, gene therapies, vaccines etc.

We have built industry's first AI framework, Leucine10x, which is designed to serve as a co-pilot in pharmaceutical manufacturing processes. Built on proprietary LLM technology, Leucine 10X offers an army of AI co-pilots that perform highly specialized tasks such as digitizing paper-based SOPs, creating a digital twin of the shop floor, collaborating with Production Managers in creating dynamic production plans, thus ensuring on-time batch delivery. Most significant is its ability to speed up Root Cause Analysis (RCA) of deviations in the manufacturing process by quickly analyzing data, including text-based records, logs, and even staff interview transcripts, to identify potential issues or patterns that might not be readily apparent.

Leucine is currently deployed at over 30 companies in over 300 pharma manufacturing facilities across 10 countries, including the US, India, Brazil, Mexico, UAE, and others. Our customers trust us in helping them deliver safe medicine in the hands of the patients across the world.

For more information visit: https://www.leucine.io

---

---